Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

NCT00543972 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
12
Enrollment
INDUSTRY
Sponsor class

Stopped due to absence of evidence of clinical activity up to toxic doses

Conditions

Interventions

Sponsor

Sanofi